



AstraZeneca in the United States

Making a positive impact
on the health of America

2026 Impact Report



Contents

AstraZeneca in the United States	3
Contributing to the US economy	5
Exporting around the world	7
Investing in transformative science	8
Strengthening the US health and innovation ecosystem	10
Improving health outcomes through collaboration	11
Addressing health disparities	12
Supporting our local communities	13
Delivering healthcare sustainably	14
Investing in our teams and fostering new talent	16
Methodology	18



AstraZeneca in the United States

At AstraZeneca, we are harnessing the power of what science can do to transform healthcare and change lives.

The United States (US), our largest market and a global engine of scientific discovery, is critical to that mission. Here, we are accelerating medical breakthroughs, powering economic growth and delivering next-generation therapies. From oncology to rare and chronic diseases, we push the boundaries of science and help innovations discovered and developed in the US reach people everywhere.

Our 23 US sites connect world-class discovery with late-stage development and advanced manufacturing, leveraging data science and artificial intelligence (AI) to move innovations from bench to bedside with speed and at scale. We work as a partner to ensure these innovations reach the people who need them and to sustain a strong, resilient US healthcare ecosystem that supports faster diagnoses, timely access, affordable care and better outcomes.

To accelerate innovation that makes a difference for patients, we are deepening our longstanding commitment to the US with a \$50 billion investment by 2030 to further expand R&D and manufacturing across the country.

AstraZeneca's US footprint in 2025

Our coast-to-coast footprint of 23 R&D, manufacturing, commercial and corporate sites employs nearly 18,000 people and supports more than 96,000 jobs across the broader economy.

In the US, AstraZeneca is home to:

Two of six global strategic R&D centers

- One in Gaithersburg, MD, with over 4,600 employees, and world-class laboratories benefiting from \$4.9 billion in annual R&D spending.
- Another strategic R&D center will open later this year in Kendall Square – the life science hub in the greater Boston, MA area. This site will house over 1,800 employees.

Our commercial business headquarters

in Wilmington, DE is home to several integral functions and employs over 1,100 employees.

23 R&D, manufacturing, commercial and corporate sites

across 11 states, Washington, DC and Puerto Rico.

12 manufacturing and supply sites


across nine states and Puerto Rico.

A new state-of-the-art cell therapy facility

in Rockville, MD.

A cutting-edge manufacturing facility

in Virginia, projected to open in 2029.



■ AstraZeneca sites ■ Coming soon



“The United States is essential to AstraZeneca’s bold ambitions for the future of medicine and to our mission of transforming healthcare through science. We are deepening our commitment to the US as a place where breakthrough science, economic growth and better outcomes for patients go hand-in-hand.”

Rick R. Suárez
US President, AstraZeneca

By the numbers in 2025



\$5.6bn

Contributed directly to the economy, creating approximately \$22 billion worth of overall value for the US economy



~18,000

People directly employed: about 19% of our total employee population



96,000+

Jobs supported across the economy



10m+

US patients treated with our medicines



~\$4.8bn

Of medicines from the US exported across the globe



\$4.9bn

Spent on R&D by US-based teams



700+

Partnerships with academia and industry to foster progress in healthcare



255

Internships provided across our sites



7,000+

Volunteer hours contributed to community initiatives impacting an estimated 100,000 lives



100+

Schools and education institutions reached by our STEM programs

Contributing to the US economy

In 2025, AstraZeneca contributed \$5.6 billion directly to the US economy¹ and employed nearly 18,000 people. Taking into account our extensive supply chain across the US, we created approximately \$22 billion in economic value and supported more than 96,000 jobs across the country.

This includes not only the people we directly employ but the thousands of roles supported through our supply chain and the everyday spending of our workforce. In other words, for every colleague at AstraZeneca, more than four jobs are supported elsewhere across the US.

The average AstraZeneca employee directly adds more than \$300,000 to the US economy each year, about 60% more than the average American worker², contributing to a high-productivity, high-wage economy.

This includes supporting high-quality employment in the manufacturing sector, where we are continuing to expand our operations. AstraZeneca's \$50 billion investment in the US includes expenditure planned across R&D and manufacturing, including cell therapy facilities in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; specialty manufacturing expansion in Coppell, Texas; and a new multi-billion dollar manufacturing facility in Virginia.

¹Measured in terms of gross value added (GVA).

²Estimated with data from Bureau of Economic Analysis and Bureau of Labor Statistics, retrieved via FRED, Federal Reserve Bank of St. Louis.

\$5.6bn

Contributed directly to the US economy

~18,000

People directly employed at AstraZeneca in the US

\$22bn

Created in economic value

96,000+

Jobs across the country



Rockville, Maryland: A new engine for US innovation and patient impact

As Maryland's largest biopharmaceutical employer, AstraZeneca is deepening its footprint with a new facility in Rockville, creating high-quality jobs and growing the community's innovation ecosystem.

This facility represents the future of cell therapy manufacturing. Built at record pace using 3D modeling, virtual reality, and AI, this state-of-the-art facility is a manufacturing trailblazer; it is set to produce CAR-T cell therapies, enabling critical cancer and immunology trials and future commercial supply in the US.

Above all else, patients are at the heart of the Rockville facility. Cell therapy is a genuine game changer with the potential to revolutionize care for cancer and other hard-to-treat diseases. This site anchors AstraZeneca's ambition to realize the full potential of cell therapies, which empowers the immune system to attack cancers, resetting the underlying drivers of autoimmune disease, and pursuing transformative solutions with curative potential for rare conditions.

Albemarle County, Virginia: Building the next generation of medicines manufacturing

AstraZeneca's next phase of US manufacturing growth includes a planned \$4.5 billion investment in Virginia, the largest single manufacturing investment in our history. The new facility is expected to create 600 highly skilled jobs, as well as around 3,000 additional indirect jobs.

This site will strengthen our US manufacturing capacity in areas of growing patient need. Upon completion, it will produce drug substances for our weight management and metabolic portfolio, and state-of-the-art manufacturing for our cancer portfolio.

To help build the talent needed to sustain this growth, AstraZeneca is also supporting a landmark workforce development partnership to advance the Virginia Advanced Pharmaceutical Manufacturing Training Network (APM Training Network). Through this industry-led collaboration, AstraZeneca is helping expand training and education opportunities across Central Virginia, working with the Commonwealth, Virginia Innovation Partnership Corporation, Virginia Economic Development Partnership, universities and community colleges to develop the next generation of advanced pharmaceutical manufacturing talent.



AstraZeneca in the United States



Exporting around the world

Pharmaceuticals are a major exporting industry for the US and reached approximately \$120 billion in 2025, marking a nearly 11.3% increase compared to 2024. This growth rate was nearly twice as high as the overall export growth for the US economy³.

AstraZeneca plays a key role in supporting this economic engine. Last year, our medicines from the US totaled nearly \$4.8 billion in exports – or about 4% of all American pharmaceutical exports.

Our US-made medicines have treated millions of patients across the Americas, Europe, Asia, Africa and Oceania. Our largest US export markets in 2025 included the United Kingdom (~\$1 billion), China (\$700+ million), Belgium (~\$500 million), Brazil (~\$500 million) and Japan (\$400+ million).



³U.S. International Trade in Goods and Services, Bureau of Economic Analysis, December and Annual 2025.
Available at: <https://www.bea.gov/news/2026/us-international-trade-goods-and-services-december-and-annual-2025>

Investing in transformative science

The pace of change in healthcare is moving more rapidly than ever before. Our patient-centric culture – from discovery to clinical trials, treatment delivery and beyond – is helping us achieve our aim of getting the right medicines to the right patients, faster than ever before.


But to achieve this, we can never be complacent about scientific discovery and development, and we believe in always pushing our R&D productivity, searching for new knowledge and the next breakthrough.

AstraZeneca is among the leading industry investors in R&D globally, investing in transformative new technologies and modalities that will shape the future of medicine.


In 2025 alone, AstraZeneca invested \$4.9 billion in R&D in the US. That includes \$1.4 billion on rare disease and chronic disease research, and \$2 billion on research into new cancer treatments.

More than 15,000 patients were enrolled in 202 AstraZeneca-sponsored clinical trials in the US, spanning a range of treatment areas.


Our investment in transformative R&D technologies includes:




Antibody drug conjugates and radioconjugates that aim to replace systemic chemotherapy and radiotherapy



Next-generation immuno-oncology bispecifics that establish new immuno-oncology segments



Cell therapy and T-cell engagers that are more scalable across therapy areas



Weight management that looks beyond short-term weight loss to address individual patient needs



Gene therapy and gene editing that could make cures possible for a range of rare diseases

Study count by therapeutic area with active participants in the US:

68

Biopharmaceutical trials

119

Oncology trials

15

Rare disease trials

15,000+

Patients enrolled across clinical trials

Advancing life-changing innovation at US R&D centers

Two of our six global strategic R&D centers are based in the US

Our scientific campus in Gaithersburg, Maryland, employs more than 4,600 experts who push the boundaries of science and pursue treatments for a wide range of conditions. With 1.3 million square feet of offices, labs and manufacturing facilities, the campus brings together discovery, development, clinical supply and manufacturing capabilities in one strategic hub, helping ideas move more efficiently from science to patients. Our work in advanced modalities and other innovative molecules strengthens our ability to translate cutting-edge research into clinical candidates at speed and scale.


Opening in 2026, our new global strategic R&D site in Cambridge, Massachusetts will be at the heart of the greater Boston life science ecosystem in Kendall Square, supporting over 1,800 R&D, commercial and corporate colleagues in 570,000 square feet of new space. The 16-story building will include 10 dedicated lab floors and was designed to foster collaboration and innovation.

Combined with the 2024 opening of Alexion's genomic medicine facility in Kendall Square, and the retention of the Alexion offices in Boston's Seaport, this growing presence underpins our commitment to the Greater Boston area.



1.3m

Square feet of offices, labs and manufacturing facilities in Gaithersburg, Maryland



570,000

Square feet of new space in Cambridge, Massachusetts



Cambridge, Massachusetts



Gaithersburg, Maryland

Strengthening the US health and innovation ecosystem

By investing in healthcare as a strategic national asset, the United States can unlock the full economic and public health value of modern medical innovation, creating lasting benefits for American families and communities.

AstraZeneca is committed to helping remove barriers that prevent people from accessing and affording the healthcare they need, so that innovative treatments reach people efficiently and equitably. Some of the ways we do this are by working with partners to:



“The early momentum following passage of the ORPHAN Cures Act reinforces the importance of policies that help foster innovation for people living with rare diseases. A more predictable policy environment can strengthen confidence in continued investment and help support the development of new treatment options for patients with significant unmet needs.”

Scott Weintraub
SVP, US Business, Alexion



Lower the cost of medicines in the US

In October 2025, we announced a historic agreement with the US Government to lower the cost of prescription medicines for American patients while preserving America’s leadership in cutting-edge biopharmaceutical innovation. The agreement advances a more balanced global approach to medicine pricing, aligning US costs with those in other wealthy countries, as well as providing direct-to-patient offerings to expand access to medications for patients living with chronic conditions in the US.



Support progress in rare disease innovation

We continue to support policies that strengthen the environment for rare disease innovation in the US, including the ORPHAN Cures Act. In the first six months following its passage, 27 orphan drugs received a second active orphan designation, targeting 22 distinct rare diseases affecting nearly 1.5 million Americans, including rare cancers and ultra-rare conditions. These early developments suggest the legislation may help provide greater certainty for continued investment in treatments for multiple rare diseases while reinforcing US leadership in rare disease innovation.



Expand access to biomarker testing

We are working to ensure that patients with cancer can access the biomarker tests that identify the most effective treatments for them. Through targeted education of state policymakers, coalition building with patient and provider organizations and digital advocacy campaigns, we have helped pass biomarker coverage laws in 23 states by end of 2025 – and are now expanding our efforts to address provider and patient awareness gaps and payer implementation barriers that continue to limit real-world testing uptake.

Improving health outcomes through collaboration

To achieve our purpose and deliver life-changing medicines, we partner with academia, governments, peer companies, biotechs, scientific organizations and patient groups to access the best science and stimulate innovation. By working together, we can accelerate delivery of new medicines to target unmet medical need.

In 2025, we engaged in more than 700 partnerships with academic institutions and industry collaborations across the US.



700+

Partnerships with academic institutions and industry collaborations across the US





Addressing health disparities

Health begins in our homes, schools and communities, and for too long, systemic barriers have prevented millions of Americans from achieving the best possible health outcomes. This leads to pervasive health inequalities.

In the US, AstraZeneca has made a long-term commitment to identify and invest in community-based solutions addressing health disparities among communities that have experienced barriers to care and opportunity. Through our ACT on Health Equity Community Investment programs, we are continuing to transform the way we do business to improve access, affordability and outcomes for patients in the disease areas and communities we serve.

Since 2021, over \$18.7 million has reached nearly 250 awardee organizations as part of our Community Solutions Challenge (CSC) and National Strategic Collaborations (NSC) grant programs. That includes Grassroots Gardens of Western New York (GGWNY), who are sharing knowledge and resources to grow healthy food, heal systemic harm and strengthen neighborhood connections through community gardens. Another CSC awardee includes There With Care of the Bay Area, an organization providing a wide range of meaningful and fundamental services to children and families during the critical phase of a medical crisis.



“When communities are empowered with the right support, they can transform health from the ground up. Our commitment is to help accelerate that change by assisting local solutions that improve care, opportunity and health outcomes.”


Mohit Manrao
Senior Vice President, Head of US Oncology,
AstraZeneca

Supporting our local communities

Power of Us

Our employee giving program – Power of Us – is designed to support employees across the US in their volunteer and giving efforts, and further cultivate AstraZeneca as a great place to work by connecting employee altruism to our business.

In 2025:



7,600

Hours committed to projects by volunteers




940

Employees volunteered their time to community initiatives across the US



285+

Community causes supported



100k

Lives impacted through reported volunteering with nonprofit and community causes

Through the power of our people getting out in communities to make a difference, our employees make an exceptional mark – impacting an estimated 100,000 lives through giving back activities in 2025.

Our Power of Us program also provides a 100% company match to employee donations made towards eligible, recognized charities and nonprofits. Together in 2025, we shared over \$3.9 million in donations to the causes that matter most to our employees.

In the same year, we provided \$52 million in corporate donations to nonprofit organizations, supporting charitable causes that impact patients and communities.

“We are so grateful for the hard work and donations AstraZeneca put together, and had a fabulous time visiting you for the event. Thank you again for everything you do.”

Community Volunteers in Medicine
Community partner




Delivering healthcare sustainably


At AstraZeneca, we embrace the role we play in transforming healthcare. We are investing in the future of medicine, but our commitment doesn't end there. We work hard to improve the health of people, society and the planet, and believe that operating sustainably is fundamental to a responsible, healthy and resilient business.

This includes reducing emissions and waste, driving efficient resource use, and working to minimize our environmental impact throughout the design and development of our medicines – from our R&D, manufacturing operations and fleet, to our use of water and materials – while continuing to grow our business.

In the United States, from 2015 to the end of 2025, AstraZeneca has:



Reduced our Scope 1 and 2 greenhouse gas emissions*



Transitioned our corporate vehicle fleet to fully electric, where technically feasible


* Excludes leased sites under 1,000m² or with less than 50 people.



“At AstraZeneca we’re taking concerted action to improve the health of people, society, and the planet. We believe our greatest impact comes when we match our ambition to transform patient outcomes through innovative science with bold action to embed sustainability into everything we do.”

Pam Cheng
Executive Vice President, Global Operations, IT and Chief Sustainability Officer, AstraZeneca

Read more in [AstraZeneca’s 2026 Sustainability Impact Report](#)



Powering our research and manufacturing sites with renewable energy


In a first-of-its-kind collaboration, AstraZeneca partnered with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of our sites in the US by the end of 2026.

To produce RNG, Vanguard Renewables works with dairy farmers and food and beverage manufacturers to use farm-based anaerobic digestion plants fueled by food and agricultural waste.

Vanguard Renewables developed three facilities – one in River Falls, WI, one in Eden WI and the latest in Amelia Court House, VA – in a joint venture with TotalEnergies. Through a strategic partnership, the RNG produced at each facility supplies AstraZeneca’s US research and manufacturing operations.

In 2025, the partnership delivered approximately 33 GWh of RNG to AstraZeneca’s US sites and will continue to ramp up supply to support the company’s US footprint. The agreement is among the most significant corporate RNG offtake commitments in the US and extends beyond energy procurement to co-development of proprietary technology that improves facility throughput and environmental impact while lowering operating costs.

By the end of 2026, the collaboration will enable as much as 650,000 million British thermal units (MMBtu), or 190,500 megawatt hours (MWh) per year, of RNG to be used across AstraZeneca’s US sites, equivalent to the energy required to heat more than 17,800 US homes for a year.



~33 GWh

Of RNG was delivered to AstraZeneca’s US sites in 2025



Investing in our teams and fostering new talent

How we do business is just as important as what we do. In all of our work, we are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.

Developing leaders of the future

Developing the treatments of the future can only happen if the pharmaceutical industry continues to invest in its workforce. That includes ensuring we are developing talent that meets future skills needs – such as a growing need for data scientists and AI specialists. It is estimated that now 30% of new drugs will be discovered with the aid of AI.⁴

To meet these emerging skills needs, AstraZeneca is committed to creating a culture of lifelong learning and development, encouraging employees to build their capabilities in digital literacy, data analytics, enterprise leadership and learning agility. At the same time, the company is investing heavily in early career talent to ensure a pipeline of future life sciences professionals.

⁴Futureproofing US Pharma Manufacturing Jobs, The International Society for Pharmaceutical Engineering (ISPE), 2025.
Available at: <https://ispe.org/pharmaceutical-engineering/ispeak/futureproofing-us-pharma-manufacturing-jobs>

In 2025 we supported:

250+ internships
across our US sites

40 opportunities
through our graduate program

31 postdoctoral positions
through our employment or funding

Our commitment to developing future talent begins with early engagement in education. AstraZeneca's science, technology, engineering and math (STEM) programs also reached more than 100 schools and education institutions in 2025, involving 600+ of our STEM ambassadors and volunteers.

We are also registered as a National Apprenticeship Sponsor through the US Department of Labor, enabling deployment of apprenticeship programs across the US. Since becoming registered, the program has been actively growing, including the launch of our first early career apprenticeships: the Maintenance Technician and Quality Control Laboratory Technician programs, which began in 2024.





Advancing workforce development through Delaware's maintenance mechanic apprenticeship

Launched in 2019, our Delaware state-registered Maintenance Mechanic apprenticeship focuses on developing talent for a role that is foundational to reliable, compliant pharmaceutical manufacturing operations.

The Newark program is building momentum and has already produced skilled graduates who have earned a Journeyman Certificate from the Delaware Department of Labor and are making meaningful contributions on site. We have active Delaware Mechanic Apprentices and recent graduates – all of whom are still with AstraZeneca.

Helping students translate classroom knowledge to real-world impact with summer internships

AstraZeneca's Summer Internship Program is a 10–12-week immersive experience, designed for undergraduate, masters-level and doctoral students. We offer the program across 10 of our US sites and, reflecting our diverse skills needs, seek majors across a range of areas: business, supply chain & communications, chemistry & life sciences, engineering, technology & data science, and safety, health & the environment.

Interns work on meaningful projects with real-world impact, helping them to integrate classroom knowledge with practical application in a supportive environment.

“The Apprenticeship Program played a key role in my growth and development by providing hands-on training with critical site systems. Working directly on these systems has helped me build a strong technical foundation while gaining confidence in troubleshooting, maintenance and safe equipment operation.

Collaborating with experienced mechanics and technicians has reinforced the importance of teamwork in maintaining reliable site operations.”

Nelvin Rivera
Apprenticeship graduate

Methodology

To value AstraZeneca's direct, supply chain (indirect) and employee spending (induced) economic impacts, Public First drew on detailed "input-output" and "supply-and-use" tables for the US economy published by the Bureau of Economic Analysis.

These tables describe the interrelationships between industry sectors in the economy, and allowed Public First to quantify economic multipliers associated with spending on different goods and services.

Economic multipliers tell us the gains to the economy in monetary and jobs terms as a result of increased spending, including not just direct impacts of such spending but also ripple-through benefits along supply chains and through employee spending.

Public First applied these economic multipliers to internal data provided by AstraZeneca US on its direct financial and employment footprint, and its procurement spending.





**Contact US Corporate
Communications:**

Jillian Gonzales
jillian.gonzales@astrazeneca.com

AstraZeneca 